Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing 1st-line chemotherapy with FOLFIRINOX or Gemcitabine/nab-paclitaxel

CONCLUSION: Patients with aPC undergoing palliative 1st-line chemotherapy with FOLFIRINOX or GN face a high risk for VTE/ATE and its diagnosis is linked to worse clinical outcomes. VTE-risk prediction models have limited ability to sub-stratify thrombotic events in this high-risk scenario.PMID:34255340 | DOI:10.1055/a-1548-4847

Source: Thrombosis and Haemostasis - July 13, 2021 Category: Hematology Authors: Jakob M Riedl Esther Schwarzenbacher Florian Moik Lena Horvath Antonia Gantschnigg Felix Renneberg Florian Posch Dominik A Barth Michael Stotz Martin Pichler Stefan Hatzl Simon Fandler-H öfler Paul Gressenberger Thomas Gary Philipp Jost Richard Greil Cih Source Type: research